Efficacy and Safety of DWC202404 and DWC202314 in Patients with Hypertension

Launched by DAEWOONG PHARMACEUTICAL CO. LTD. · Nov 7, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness and safety of two medications, DWC202404 and DWC202314, when used together to help lower blood pressure in patients who have high blood pressure (hypertension) that is not well controlled with just DWC202404 alone. The trial is in its third phase, which means it is testing the treatments on a larger group of people to see how well they work and if they are safe.

To participate in the trial, individuals must be aged 39 or older and have a specific range of blood pressure readings, depending on whether they are currently taking blood pressure medications. For those not on medication, their blood pressure should be between 140 and 180 mmHg, and for those already taking medication, it should be between 130 and 180 mmHg. Participants will be randomly assigned to receive either the combination of the two medications or a placebo (a treatment that looks like the medication but has no active ingredients) and will be monitored closely for changes in their blood pressure and any side effects. This trial aims to find better ways to manage high blood pressure and improve overall health for those affected.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Average systolic blood pressure (MSSBP) measured at the time of screening meet the following criteria (a) If anti-hypertensive drugs are not being administered: 140 mmHg ≤ MSSBP \< 180 mmHg (b) If anti-hypertensive drugs are being administered: 130 mmHg ≤ MSSBP \< 180 mmHg
• Exclusion Criteria:
• • If the blood pressure measured at the time of screening and randomization is MSDBP ≥ 110 mmHg
• • Those whose blood pressure differences measured on both arms at the time of screening are MSSBP ≥ 20 mmHg and MSDBP ≥ 10 mmHg